Semantic Scholar uses AI to extract papers important to this topic.
A novel coronavirus SARS-CoV-2, also called novel coronavirus 2019 (nCoV-19), started to circulate among humans around December… Expand BACKGROUND & AIMS
We investigated the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment… Expand BACKGROUND
All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated… Expand BACKGROUND
Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon… Expand Background Peginterferon–ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV… Expand BACKGROUND
In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to… Expand BACKGROUND
Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV… Expand BACKGROUND
Peginterferon plus ribavirin achieves sustained virological response (SVR) in fewer than half of patients with… Expand Boceprevir is a hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease inhibitor that is currently being evaluated in… Expand More than 170 million people worldwide are affected by the hepatitis C virus (HCV). The disease has been described as a "silent… Expand